<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A new series of 1,4-benzoxazepine derivatives was designed, synthesized, and evaluated for binding to 5-HT1A receptor and cerebral anti-ischemic effect </plain></SENT>
<SENT sid="1" pm="."><plain>A lot of compounds exhibited nanomolar affinity for 5-HT1A receptor with good selectivity over both <z:chebi fb="40" ids="18243">dopamine</z:chebi> D2 and alpha1-adrenergic receptors </plain></SENT>
<SENT sid="2" pm="."><plain>Among these compounds, 3-chloro-4-[4-[4-(2-<z:chebi fb="0" ids="51635">pyridinyl</z:chebi>)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1, 4-benzoxazepin-5(4H)-one (50: SUN N4057 (Piclozotan) as 2HCl salt) showed remarkable neuroprotective activity in a transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (t-MCAO) model </plain></SENT>
</text></document>